Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal cebranopadol abuse potential study
NCT06453265Phase 1Completed
- Sponsor
- Tris Pharma
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cebranopadol (8 arms), sponsored by Tris Pharma. Primary endpoint: Drug Liking Visual Analog Scale Maximum Effect at 48 hours. Started Jun 2024; status: completed.
02
Drugs
cebranopadol
Beyond the preview
Go deeper on NCT06453265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06453265.